so honored and excited tos hare on behalf of all our team and co-investigators the results of RUBY study #EditasMedicine that used novel first-in human CRISPR-Cas12a Gene Editing of HBG1 & HBG2 Promoters to treat #SickleCell Disease which was published today in @nejm.org www.nejm.org/doi/full/10....

#EditasMedicine #CRISPR achieving apparent 40-50%* editing in hematopoietic stem cells after just a SINGLE LNP admin in non-human primates is impressive.

In vivo sickle cell CRISPR cannot come fast enough. Tech getting close.

*still increasing at 3 months